Group 1 - The core issue is the continuous financial fraud by *ST Changyao, with the China Securities Regulatory Commission (CSRC) announcing administrative penalties for false financial reporting from 2021 to 2023 [1][4] - The CSRC plans to impose a fine of 10 million yuan on the company and a total of 31 million yuan on 14 responsible individuals, with a total penalty of 41 million yuan [1][4] - The former general manager, Luo Ming, will face a lifetime ban from the securities market [1][4] Group 2 - The company’s stock price has fallen below 1 yuan, triggering a delisting warning [1][4] - Investors are urged to register for compensation, with updated eligibility criteria for claims based on specific purchase and sale dates [1][5] - The company is facing mandatory delisting due to serious violations, with the Shenzhen Stock Exchange initiating delisting procedures [1][5] Group 3 - The financial fraud stemmed from performance pressure following the acquisition of Hubei Changjiang Xing Pharmaceutical Co., Ltd., with commitments made by the original controlling person, Luo Ming, regarding profit targets from 2020 to 2022 [2][5] - Between 2021 and 2023, subsidiaries of Changyao fabricated inventory documents to recognize revenue without actual sales [2][5] Group 4 - The fraudulent financial reports inflated operating income by 215.32 million yuan, 283.74 million yuan, and 233.63 million yuan for the years 2021, 2022, and 2023, respectively [3][6] - The auditing firms for the relevant years will also be investigated and may face penalties, being included as co-defendants in future compensation lawsuits [3][6]

*ST长药（维权）(300391.SZ)今日20cm跌停，报0.94元，股价跌破1元关口，并创历史新低，年内累跌逾81%。*ST长药公告称，收到湖北省十堰市中级人民 法院送达的《民事裁定书》和《决定书》，法院裁定不予受理十堰市郧胥工贸有限公司对公司的重整申请，并终结公司预重整程序。同时，法院裁定终止湖 北长江星医药股份有限公司等七家公司实质合并重整程序，宣告这些公司破产。此外，公司因涉嫌定期报告等财务数据虚假记载，被中国证监会立案调查， 可能触及重大违法强制退市情形。公司股票自2025年4月22日起被实施退市风险警示和其他风险警示。(格隆汇) ...

许峰律师代理的长药控股投资者索赔案已向武汉市中级人民法院提交立案，目前正在等待法院的下一步 安排，律师团队同步还在继续推进后续案件的立案工作，还在继续接受其他投资者的索赔委托，长药控 股投资者索赔案已有投资者胜诉先例。 2025年12月26日，长药控股公告收到证监会下发的《行政处罚事先告知书》，根据《告知书》认定的事 实，公司2021年、2022年、2023年年度报告存在虚假记载，2021年至2023年年度报告分别虚增营业收入 21，532.38万元、28，373.66万元、23，363.46万元，占当期对外披露营业收入的9.12%、17.57%、 19.51%；虚增利润总额5，640.14万元、6，337.52万元、4，370.50万元，占当期对外披露利润总额绝对 值的35.62%、88.23%、6.42%。同时，由于2022年对长江伟创中药城交易中心工程项目未合理确认损 失，导致公司2022年年度报告虚增利润总额455.24万元，占当期对外披露利润总额的6.34%。公司可能 触及《深圳证券交易所创业板股票上市规则》第10.5.2条第（六）项的"根据中国证监会行政处罚决定载 明的事实，公司披露的年度报告财务 ...

图片由AI生成 今日，*ST长药（长江医药控股股份有限公司，股票代码300391.SZ）竞价阶段即封死跌停，股价报1.18元/股，总市值仅剩4.13亿元。 晚间公司同步披露：收到湖北省十堰市中级人民法院裁定，不予受理其重整申请并终结预重整程序，旗下湖北长江星医药等七家子公司实质合并重整程序终 止且被宣告破产。 这场双重崩塌的背后，是12月26日证监会下发的《行政处罚事先告知书》——公司2021年至2023年连续三年财务造假，累计虚增营收7.33亿元、利润1.68亿 元，已触及重大违法强制退市红线，被叠加实施退市风险警示。 距年末仅剩两天，债务豁免、注资等保壳动作已无落地时间窗口，-6.43亿净资产无法转正，财务类退市与重大违法退市双重风险叠加，加之重整之路全面 终结，这家跨界"光伏+医药"的上市公司，终因长期造假与经营溃败走向末路。 | 最高: 1.18 | 今开: 1.18 | 涨停:1.76 | | --- | --- | --- | | 曼低:1.18 | 昨收:1.47 | 跌停:1.18 | | 换手:2.54% | 盘后量:32手 | 量比:0.19 | | 振幅:0.00% | 盘后额:3776 ...

Core Viewpoint - *ST Changyao (300391.SZ) has received court rulings that terminate its pre-restructuring process and reject a restructuring application from a related company, indicating significant challenges in its financial recovery efforts [1] Group 1: Court Rulings - The Hubei Shiyan Intermediate People's Court has ruled not to accept the restructuring application from Shiyan Yunxu Industrial and Trade Co., Ltd. against the company, effectively ending the pre-restructuring process [1] - The court also issued a ruling to terminate the substantive merger restructuring process for Hubei Changjiang Star Pharmaceutical Co., Ltd. and seven other companies, declaring them bankrupt [1]

关于法院裁定不予受理重整申请 暨子公司宣告破产的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 证券代码：300391 证券简称：*ST长药 公告编号：2025-107 长江医药控股股份有限公司 特别提示： 1、2025年12月29日，长江医药控股股份有限公司（以下简称"公司"或"长 药控股"）收到湖北省十堰市中级人民法院送达的（2024）鄂03破申76号《民事裁 定书》、（2024）鄂03破申76号之三《决定书》，法院裁定不予受理十堰市郧胥工 贸有限公司对公司的重整申请，决定依法终结公司预重整程序。同日，公司收到湖 北省十堰市中级人民法院送达的（2025）鄂03破1号《民事裁定书》，法院裁定终 止湖北长江星医药股份有限公司等七家公司实质合并重整程序，宣告湖北长江星医 药股份有限公司等七家公司破产。 2、公司因涉嫌定期报告等财务数据虚假记载，被中国证券监督管理委员会（ 以下简称"中国证监会"）立案调查。公司及相关人员于2025年12月26日收到中国 证监会下发的《行政处罚事先告知书》（以下简称"《告知书》"）。根据《告知 书》认定的事实，公司2021年、2 ...

Core Viewpoint - The traditional Chinese medicine sector experienced a decline of 0.9% on December 29, with *ST Changyao leading the drop. The Shanghai Composite Index closed at 3965.28, up 0.04%, while the Shenzhen Component Index closed at 13537.1, down 0.49% [1]. Group 1: Stock Performance - The following stocks in the traditional Chinese medicine sector showed notable performance: - WoHua Pharmaceutical (002107) closed at 6.33, up 2.43% with a trading volume of 106,100 shares and a transaction value of 65.58 million yuan [1]. - Tianmu Pharmaceutical (600671) closed at 17.39, up 1.81% with a trading volume of 22,600 shares and a transaction value of 39.17 million yuan [1]. - Weikang Pharmaceutical (300878) closed at 25.75, up 0.66% with a trading volume of 20,500 shares and a transaction value of 53.04 million yuan [1]. - Tongrentang (600085) closed at 32.46, up 0.65% with a trading volume of 168,300 shares and a transaction value of 221 million yuan [1]. - Yunnan Baiyao (000538) closed at 56.69, down 0.02% with a trading volume of 61,100 shares and a transaction value of 346 million yuan [1]. Group 2: Capital Flow - The traditional Chinese medicine sector saw a net outflow of 689 million yuan from institutional investors, while retail investors contributed a net inflow of 462 million yuan [2]. - Notable capital flows for specific stocks include: - Tongrentang (600085) had a net inflow of 28.03 million yuan from institutional investors, but a net outflow of 19.15 million yuan from retail investors [3]. - Wanbangde (002082) experienced a net inflow of 12.49 million yuan from institutional investors, with a net outflow of 9.44 million yuan from retail investors [3]. - Ma Yinglong (600993) had a net inflow of 5.11 million yuan from institutional investors, while retail investors saw a net inflow of 3.19 million yuan [3].

【导读】商业航天板块持续活跃，神剑股份 8 连板；锂电股集体下挫； *ST 长药 20cm 跌 停 中国基金报记者 晨曦 大家好！又到周一，来一起关注最新的市场行情和资讯 ~ 12 月 29 日， A 股三大指数开盘涨跌不一，上证指数高开 0.02% ，深证成指平开，创业板 指跌 0.19% 。开盘后，市场持续分化。截至发稿，上证指数涨 0.19% ，创业板指跌 0.83% 。 热门板块中，上午商业航天板块持续火热，神剑股份走出 8 连板；化学纤维、稀土、 GPU 等方向活跃；锂电、动力电池、玻璃纤维、 SPD 等概念股回调。 | 商业航天 | 2249.140 | 0.35% | 7.855 | | --- | --- | --- | --- | | 886078.TI | | | | | 光威复材 | 39.80 - | 14.14% | 4.93 | | 创 300699.SZ | | | | | 斯瑞新材 | 42.78 | 12.94% | 4.90 | | 科创 688102.SH | | | | | 中超控股 | 6.89 | 10.06% | 0.63 | | 002471.SZ | | | ...

Core Viewpoint - The company *ST Changyao is focusing on becoming a leading platform in the health industry, primarily engaged in the production and sales of traditional Chinese medicine, medicinal capsules, and the wholesale of pharmaceuticals, health products, and medical devices [1][10]. Group 1: Company Overview - *ST Changyao is classified under the pharmaceutical and biological sector, specifically in traditional Chinese medicine [2][10]. - The company aims to build an integrated pharmaceutical industry chain that includes the production of traditional Chinese medicine, hollow capsules, and a medical logistics network [1]. Group 2: Financial Misconduct - On November 7, 2025, the company received a notice from the China Securities Regulatory Commission regarding suspected false reporting of financial data [2][10]. - The company reported inflated revenues for 2021, 2022, and 2023, amounting to 215.32 million, 283.74 million, and 233.63 million yuan respectively, which represented 9.12%, 17.57%, and 19.51% of the disclosed revenues for those years [5][12]. - The inflated total profits for the same years were reported as 56.40 million, 63.38 million, and 43.71 million yuan, accounting for 35.62%, 88.23%, and 6.42% of the disclosed total profits [5][12]. Group 3: Investor Compensation - Investors who purchased shares between April 28, 2022, and November 7, 2025, and sold or continued to hold them after November 8, 2025, are eligible for compensation [5][12]. - Additionally, investors who bought shares between March 30, 2019, and April 29, 2024, and sold or continued to hold them after April 30, 2024, can also participate in the compensation [9][15]. Group 4: Financial Issues and Risks - As of April 30, 2024, the company disclosed significant financial issues, including a fund occupation amounting to 179.66 million yuan, which is 92.08% of the latest audited net assets [6][14]. - The company has acknowledged internal control deficiencies regarding non-operational fund occupation by its former general manager and related parties from 2019 to 2023 [7][14].

Core Viewpoint - Changjiang Pharmaceutical Holdings Co., Ltd. (*ST Changyao) is facing administrative penalties from the China Securities Regulatory Commission (CSRC) for financial misconduct, including false reporting of revenue and profits over multiple years [2][6]. Group 1: Financial Misconduct - The company acquired 52.75% of Hubei Changjiang Xing Pharmaceutical Co., Ltd. in November 2020, which was subsequently consolidated into its financial statements [2][6]. - From 2021 to 2023, the subsidiaries of Changjiang Xing fabricated inventory and sales documents, leading to inflated revenues of CNY 215.32 million, CNY 283.74 million, and CNY 233.63 million, representing 9.12%, 17.57%, and 19.51% of reported revenues respectively [2][6]. - The inflated total profits during the same period were CNY 56.40 million, CNY 63.38 million, and CNY 43.71 million, accounting for 35.62%, 88.23%, and 6.42% of the reported total profits [2][6]. Group 2: Potential Consequences - The company may face mandatory delisting due to continuous false reporting of financial indicators over three years, as per the Shenzhen Stock Exchange rules [3][7]. - On November 7, 2025, the company announced it was under investigation for suspected false reporting of financial data [8]. Group 3: Investor Compensation - A law firm is collecting claims from investors who purchased shares between April 28, 2022, and November 6, 2025, and either sold or held the shares after November 7, 2025 [4][8]. - Investors may seek civil compensation for losses incurred due to the company's fraudulent activities, which could include differences in investment, commissions, and stamp duties [8].